Clinical trials: Myeloma, Plasma-Cell
Relapse Multiple Myeloma
Melflufen for Elderly Patients With Relapsed Myeloma
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse. Thirty elderly patients at second or subsequent relapse.
- Trial name
- NCT06682637
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Italy
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma, Relapse Multiple Myeloma
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
For the treatment of relapsed and refractory MM, the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma pointed out that relapsed MM is highly heterogeneous, and individualized evaluation of relapsed patients…
- Conditions
- Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT05150522
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Multiple Myeloma, Lymphoma
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
Chemokine receptor CXCR4 was expressed in MM and lymphoma cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of MM and lymphoma with higher accuracy.
- Trial name
- NCT03436342
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Peripheral Neuropathy, Multiple Myeloma, Neoplasms
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
This study aims at evaluating the possible beneficial role of Fenofibrate in attenuating the peripheral neuropathy associated with bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen in newly diagnosed…
- Trial name
- VRd MM Fibrate (NCT07025005)
- Testing
- Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone
- Where
- 2 sites in Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Multiple Myeloma
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore…
- Trial name
- NCT00572169
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Arkansas
Myeloma, Newly Diagnosed
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive lenalidomide,bortezomib, and…
- Conditions
- Myeloma, Newly Diagnosed, High Risk
- Trial name
- NCT03641456
- Testing
- bortezomib, Lenalidomide, Dexamethasone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma in Relapse
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies.
- Trial name
- AmbuSpé (NCT06846905)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Toulouse
Relapsed Multiple Myeloma
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
Anti-apoptotic proteins from the Bcl-2 family are known to play a key role in oncogenesis and are overexpressed in myeloma cells.
- Trial name
- NCT01272466
- Testing
- peptides derived from antiapoptotic proteins
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Herlev Hospital
Multiple Myeloma
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
- Trial name
- NCT01234129
- Testing
- zoledronic acid
- Where
- Mexico
- Volunteers
- 320 people
- Sponsor
- Instituto Mexicano del Seguro Social
Cancer, Myeloma
Imageguided Theranostics in Multiple Myeloma
Theranostics is the use of a diagnostic test to decide which patients will benefit from a certain treatment. The current standard treatment for patients with myeloma is induction chemotherapy followed by peripheral stem cell…
- Trial name
- iTIMM (NCT02403102)
- Where
- United Kingdom
- Volunteers
- 61 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Multiple Myeloma
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization).
- Trial name
- DRAMMATIC (NCT04071457)
- Testing
- Lenalidomide, Daratumumab/rHuPH20
- Where
- 842 sites in United States, Canada
- Volunteers
- 1,100 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of…
- Trial name
- MY MYELOMA (NCT05001087)
- Testing
- Observation
- Where
- 27 sites in Italy
- Volunteers
- 1,900 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation…
- Trial name
- NCT00891384
- Testing
- Lenalidomide
- Where
- 5 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Multiple Myeloma
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction
The purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.
- Trial name
- IFM-CRd (NCT02405364)
- Testing
- Carfilzomib/Lenalidomide/Dexamethasone
- Where
- 11 sites in France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Toulouse
Refractory Multiple Myeloma
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
- Trial name
- NCT00912899
- Testing
- Noscapine HCl
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cougar Biotechnology, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003399
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
CS1+ or BCMA+ Multiple Myeloma
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT04662099
- Testing
- Conditioning chemotherapy followed by CAR T cell infusion
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.